Key facts
- It has raised $28.7M; the latest was Accelerator/Incubator in May 2025.
- Notable investors include MedTech Innovator, CNT Tech, SBVA, Korea Investment & Securities, Y&Archer — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Heuron
- ·The full record, as it builds
Funding rounds
No funding rounds for Heuron are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Heuron
Developer of an artificial intelligence-based image analysis medical device intended for neurological disease diagnosis. The company offers magnetic resonance imaging (MRI) diagnosis software for rapid and accurate medical response by implementing the diagnostic logic of professional clinicians into an AI model, enabling medical professionals to facilitate the accurate and early diagnosis of Alzheimer's and Parkinson's disease with early diagnosis, staging, traceability and identifying brain damage levels.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2017
- Employees
- 49
- Website
- iheuron.com/
- Ownership
- Privately Held (backing)
Heuron doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Heuron shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Heuron in its N-PORT filings yet. We sweep new filings monthly.